Docetaxel in Treating Patients With Advanced Cancer of the Cervix

Phase 2

Completed

• Conditions: Cervical Cancer

• Registration Number: NCT00003445
• Lead Sponsor: Grupo Oncologico Cooperativo del Sur

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with advanced cancer of the cervix.

Detailed Description

OBJECTIVES: I. Assess the antitumor activity of docetaxel as neoadjuvant chemotherapy in patients with locally advanced squamous cell carcinoma of the cervix. II. Assess the tumor response, toxic effect, and survival rate of this regimen in these patients.

OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Treatment is repeated every 3 weeks for 3 courses. Patients are followed every 3 months posttreatment.

PROJECTED ACCRUAL: A total of 16-35 patients will be accrued for this study.

Study Timeline

• Study Start: 1997-12
• Study First Submitted: 1999-11-01
• Status Verified: 2001-09
• Study Completion: 2004-04
• Study First Submitted QC: 2004-04-22
• Study First Posted: 2004-04-23
• Last Update Submitted: 2013-06-25
• Last Update Posted: 2013-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Unidad Oncologica Del Comahue; 🇦🇷 Neuquen, Argentina